The TIME has come under renewed and intense interest with the success of cancer immunotherapy using immune checkpoint inhibitors that target proteins such as programmed cell death protein 1 (PD-1, a T-cell co-inhibitory receptor) or programmed death ligand 1 (PD-L1, also called B7-H1 or CD274) [1, 2]. Here, PDCD1 is linked to cancer.